Avidity Biosciences, Inc. (RNA): A Bull Case Theory 

We came across a bullish thesis on Avidity Biosciences, Inc. on BiotechBonanza’s Substack by  AnotherBio. In this article, we will summarize the bulls’ thesis on RNA. Avidity Biosciences, Inc.'s share was trading at $71.54 as of December 2nd.

[caption id="attachment_575382" align="aligncenter" width="750"] Tonhom1009/Shutterstock.com[/caption]

Novartis is acquiring Avidity RNA, a pre-Phase 3 biotech company, in a straightforward deal with no overlap between the two businesses. The transaction is expected to close in the first half of 2026, though timing uncertainty exists...